Login
$ARMP
$2.99 -$0.88 (22.74%) Live

Company Executives

Officer Age In this role 2025 pay Source
Deborah L. Birx Also a director
Chief Executive Officer and Director
70 Not stated $1,249,889
David D. House
Chief Financial Officer
42 Not stated $554,770
Pierre Kyme
Chief Business Officer
48 Since 2024
2 years
$791,575

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
6 of 7
stated in the proxy; 1 not stated
Average tenure
5.0 years
from year joined
CEO also chairs the board
No
Robin C. Kramer
Director Age On board Independent Committees Other public boards 2025 pay Source
Robin C. Kramer
61 2020
6 years
Independent
Special Committee
None stated $180,902
Deborah L. Birx
70 Not stated Not independent None stated None stated Paid as CEO
Daniel B. Gilmer
39 2026
this year
Independent None stated None stated Not stated
Jules Haimovitz
75 2021
5 years
Independent None stated None stated $128,902
Odysseas D. Kostas
52 2020
6 years
Independent
Nominating and Corporate Governance
Amarin Corporation $132,902
Joseph M. Patti
62 2019
7 years
Independent
Nominating and Corporate Governance
None stated $154,902
Sarah J. Schlesinger
66 2020
6 years
Independent
Compensation
Innoviva, Inc. $142,902
Todd C. Peterson Leaving at the meeting
Not stated Not stated Not stated
Audit Special Committee
None stated $141,902

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

6 disclosed in the proxy filed Apr 27, 2026
Innoviva Sub
$15.0 million
August 11, 2025

August 2025 credit and security agreement loan of $15.0 million at 14.0% annual interest, maturing January 11, 2029, secured by substantially all assets.

With the Company Open in proxy
Innoviva Sub
$10.0 million
March 12, 2025

March 2025 credit and security agreement loan of $10.0 million at 14.0% annual interest, maturing June 1, 2027, secured by substantially all assets.

With the Company Open in proxy
Innoviva Sub
$35.0 million
March 4, 2024

2024 secured term loan facility of $35.0 million at 14.0% annual interest, scheduled to mature June 1, 2027.

With the Company Open in proxy
Innoviva Sub
$25.0 million
July 10, 2023

2023 secured term loan facility of $25.0 million at 14.0% annual interest, scheduled to mature June 1, 2027.

With the Company Open in proxy
Innoviva
$30.0 million
January 10, 2023

Convertible loan of $30.0 million at 8.0% annual interest, scheduled to mature June 1, 2027, convertible into common stock under stated terms.

With the Company Open in proxy
Innoviva Sub
Amount not stated
January 23, 2026

January 2026 amendments extending the maturity dates of the credit agreements to June 1, 2027 and extending expiration dates of warrants held by Innoviva Sub to January 26, 2031.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support